SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 1.1% Passive Stake in Immunic, Inc.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 1.1% beneficial ownership stake in Immunic, Inc. through an Amendment No. 4 to Schedule 13G filing.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Immunic, Inc.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 1,026,762 shares of Immunic, Inc. Common Stock.
• This ownership represents 1.1% of the company's outstanding Common Stock.
• The reported shares include warrants held by the Reporting Persons to purchase 1,026,762 shares.
• The percentage is calculated based on 90,150,869 shares outstanding, as reported by Immunic, Inc. in its Prospectus filed on April 9, 2025.
• The filing indicates shared voting power and shared dispositive power over all 1,026,762 shares.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of passive beneficial ownership. It neither indicates strong positive nor negative sentiment regarding the issuer's performance or prospects, but rather a routine update on an investment position.

Positives

• RTW Investments, a notable investment firm, maintains a stake in Immunic, Inc., potentially indicating continued confidence in the company's long-term prospects.

Negatives

• The filing itself does not contain negative financial or operational information about Immunic, Inc.; it is a routine disclosure of ownership.

Risks

• The document is a disclosure of beneficial ownership and does not explicitly state risks related to Immunic, Inc.'s operations or financial health.

Future Outlook

The document is a passive ownership disclosure and does not contain forward-looking statements or guidance from Immunic, Inc. or the Reporting Persons regarding the issuer's future outlook.

Industry Context

This filing is a routine disclosure of passive ownership by an investment firm in a publicly traded company. It does not provide specific industry trends or competitive analysis, but it indicates continued investment interest in the biopharmaceutical sector, where Immunic, Inc. operates.

Stakeholder Impact

• This filing primarily impacts shareholders by providing transparency on significant passive ownership stakes. It does not directly detail impacts on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Immunic Inc, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology